Jiangsu Recbio Technology Co EBIT Margin

What does Jiangsu Recbio Technology Co do? Jiangsu Recbio Technology Co., Ltd. generates revenue through the research and development of vaccines, focusing on clinical-stage and pre-clinical-stage products. The company develops recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b, alongside Covid-19 vaccine development. Its primary market is the domestic Chinese market, where it distributes these vaccines to healthcare providers and government health programs. The firm's product portfolio includes HPV vaccine pipelines such as REC603, REC601, REC602, REC604a, and REC604b, all targeting cervical cancer prevention. These vaccines are developed for the domestic market, with no mention of international distribution. The company's revenue streams are derived from the sale of these vaccines once they reach commercialization, supported by its 434 full-time employees in research and development. Jiangsu Recbio Technology operates with a focus on vaccine innovation, leveraging its clinical-stage and pre-clinical-stage pipelines to address unmet medical needs. The company's domestic market strategy ensures that its products are distributed through established healthcare channels within China, aligning with the country's public health initiatives and vaccine procurement programs. Jiangsu Recbio Technology Co is one of the most popular companies on Eulerpool.